logo

Curis Inc (CRIS)



Trade CRIS now with
  Date
  Headline
5/5/2022 4:06:08 PM Curis Q1 Loss/share $0.18 Vs. Loss $0.11 Year Ago
4/11/2022 8:03:07 AM Curis Announces FDA Partial Clinical Hold For TakeAim Lymphoma Study Of Emavusertib On B-cell Malignancies
4/4/2022 7:04:19 AM Curis Announces FDA Places Partial Clinical Hold For TakeAim Leukemia Study Of Emavusertib
2/24/2022 4:06:26 PM Curis Reports Q4 Loss Per Share Of $0.15 Vs. Loss Per Share Of $0.11 Last Year
1/6/2022 10:59:07 AM Curis Shares Down 27%
1/6/2022 7:05:22 AM Curis Reports Data With Addl Clinical Activity In Phase 1/2 Study Of CA-4948 Monotherapy In Relapsed/Refractory AML,MDS
11/9/2021 4:03:39 PM Curis Inc Q3 Earnings Summary
11/9/2021 4:03:01 PM Curis Q4 Loss/share $0.12 Vs. Loss $0.11 Year Ago
11/9/2021 8:03:05 AM Curis Announces New Preclinical Data For CI-8993 At The Society For Immunotherapy Of Cancer
11/8/2021 8:04:48 AM Curis Says First Patient Dosed In Phase 1/2 Study Of CA-4948 In Patients With Refractory Acute Myeloid Leukemia
10/7/2021 9:10:23 AM Curis Presents Data Highlights Potential Of CA-4948 In Multiple Hematologic Malignancies On Molecular Targets
8/3/2021 4:07:17 PM Curis Reports Q2 Loss Per Share Of $0.12 Vs. $0.17 Last Year